Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Treating antiretroviral-induced dyslipidemia in HIV-infected adults.

Scordo KA.

Nurse Pract. 2010 Jul;35(7):32-7; quiz 37-8. doi: 10.1097/01.NPR.0000383658.60403.6b. No abstract available.

PMID:
20555242
2.

Antiretroviral and statin drug-drug interactions.

Ray GM.

Cardiol Rev. 2009 Jan-Feb;17(1):44-7. doi: 10.1097/CRD.0b013e3181903b7f. Review.

PMID:
19092370
3.

Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

Behrens GM.

N Engl J Med. 2005 Apr 21;352(16):1721-2; author reply 1721-2. No abstract available.

4.

Dyslipidemias in chronic kidney disease.

Szromba C.

Nephrol Nurs J. 2006 Sep-Oct;33(5):575-6. No abstract available.

PMID:
17044444
5.

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr.

J Infect. 2004 Nov;49(4):283-90.

PMID:
15474625
6.

HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.

Nolan DP, O'Connor MB, O'Connor C, Moriarty M, O'Leary A, Bergin C.

Int J STD AIDS. 2010 Jan;21(1):75-6. doi: 10.1258/ijsa.2009.009364. No abstract available.

PMID:
19884356
7.

Dyslipidemia related to antiretroviral therapy.

Estrada V, Portilla J.

AIDS Rev. 2011 Jan-Mar;13(1):49-56. Review.

PMID:
21412389
8.

Clinical management considerations for dyslipidemia in HIV-infected individuals.

Kirchner JT.

Postgrad Med. 2012 Jan;124(1):31-40. doi: 10.3810/pgm.2012.01.2515. Review.

PMID:
22314112
9.

Dyslipidemia and lipid-lowering therapy in the elderly.

Deedwania P, Volkova N.

Expert Rev Cardiovasc Ther. 2005 May;3(3):453-63. Review.

PMID:
15889973
10.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
12.
13.

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

Negredo E, Moltó J, Puig J, Cinquegrana D, Bonjoch A, Pérez-Alvarez N, López-Blázquez R, Blanco A, Clotet B, Rey-Joly C.

AIDS. 2006 Nov 14;20(17):2159-64.

PMID:
17086055
14.

[Cardiovascular risk in HIV infected patients].

Raimundo P, Miranda A, Ribeiro J, Mansinho K.

Acta Med Port. 2010 Jul-Aug;23(4):669-76. Review. Portuguese.

15.

Safety of statin therapy in HIV/hepatitis C virus-coinfected patients.

Milazzo L, Menzaghi B, Corvasce S, Bonfanti P, Rusconi S, Ridolfo AL, Antinori S.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):258-60. No abstract available.

PMID:
17895771
16.

[HAART influences the lipids].

Behrens G.

MMW Fortschr Med. 2009 Apr 30;151(18):36-8. German. No abstract available.

PMID:
19769073
17.
18.

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

BHIVA Writing Committee.; BHIVA Executive Committee..

HIV Med. 2001 Oct;2(4):276-313. No abstract available.

19.

Cardiovascular implications of HIV-induced dyslipidemia.

Giannarelli C, Klein RS, Badimon JJ.

Atherosclerosis. 2011 Dec;219(2):384-9. doi: 10.1016/j.atherosclerosis.2011.06.003. Review.

PMID:
21722900
20.

HIV meds: keeping trouble at bay.

Daughtry LM, Bankston JB, Deshotels JM.

RN. 2002 Feb;65(2):31-5; quiz 36. No abstract available.

PMID:
15328865
Items per page

Supplemental Content

Support Center